Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 2Endocrine 2CNS 2

Conditions

Carcinoma, Renal Cell 24Kidney Neoplasms 8von Hippel-Lindau Disease 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Pheochromocytoma 2Paraganglioma 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Hemangioblastoma 1Glioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

belzutifan 5gallium Ga 68 dotatate 3Everolimus 2Blood Specimen Collection 2vatalanib 1tanespimycin 1spartalizumab 1palbociclib 1lenvatinib 1cabozantinib 1Vorinostat 1Sunitinib 1Ranibizumab 1Propranolol 1PT2385 1Oxygen-15 1Nivolumab 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Exome Sequencing 1Bevacizumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
von Hippel-Lindau Disease × belzutifan × Clear all
NCT07405164 2026-05-29

MK-6482-043

Merck Sharp & Dohme LLC

Phase 3 Recruiting
450 enrolled
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT03401788 2026-04-13

MK-6482-004

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting
50 enrolled 1 FDA

von Hippel-Lindau Disease

NCT07167329 2025-09-11

BELIEVE-VHL

AC Camargo Cancer Center

Phase 2 Recruiting
100 enrolled
CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT06554730 2024-11-29

MK-6482-026

Merck Sharp & Dohme LLC

Withdrawn

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡